

Sheet 1 of 6

| | | | |
|---|---|---|---------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 21, 2003 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 2732.1016-029 | APPLICATION NO. 10/719,432 Cont. App. of 09/841,379 | |
| | APPLICANT Spiros Jamas <i>et al.</i> | | |
| | FILING DATE | CONFIRMATION NO. | GROUP 1614 |

| U.S. PATENT DOCUMENTS | | | | |
|-------------------------------|-------------|-----------------|----------------------------------|-------------------------|
| EXAM- INER INI- TIAL | REF. NO. | DOCUMENT NUMBER | ISSUE DATE / PUBLICATION DATE | NAME |
| <i>mm</i> | AA | 4,810,646 | 03/07/89 | Jamas <i>et al.</i> |
| | AB | 4,761,402 | 08/02/88 | Williams <i>et al.</i> |
| | AC | 4,739,046 | 04/19/88 | DiLuzio <i>et al.</i> |
| | AD | 4,138,479 | 02/06/79 | Truscheit <i>et al.</i> |
| | AE | 4,237,266 | 12/02/80 | Sugiura <i>et al.</i> |
| | AF | 4,707,471 | 11/17/87 | Larm <i>et al.</i> |
| | AG | 5,032,401 | 07/16/91 | Jamas <i>et al.</i> |
| | AH | 5,057,503 | 10/15/91 | Czop <i>et al.</i> |
| | AI | 5,322,841 | 11/02/92 | Jamas <i>et al.</i> |
| | AJ | 5,320,849 | 06/14/94 | Hagiwara <i>et al.</i> |
| | AK | 5,488,040 | 01/30/96 | Jamas <i>et al.</i> |
| | AA2 | 5,532,223 | 07/02/96 | Jamas <i>et al.</i> |
| | AB2 | 5,622,939 | 04/22/97 | Jamas <i>et al.</i> |
| | AC2 | 3,943,247 | 03/09/76 | Komatsu <i>et al.</i> |
| | AD2 | 5,504,079 | 04/02/96 | Jamas <i>et al.</i> |
| | AE2 | 5,401,647 | 03/28/95 | Tanaka <i>et al.</i> |
| | AF2 | 5,783,569 | 7/21/98 | Jamas <i>et al.</i> |
| | AG2 | 5,817,643 | 10/06/98 | Jamas <i>et al.</i> |
| | AH2 | 4,975,421 | 12/04/90 | Williams <i>et al.</i> |
| | AI2 | 5,474,984 | 12/12/95 | Tanaka <i>et al.</i> |
| | AJ2 | 4,946,450 | 08/07/90 | Erwin |
| | AK2 | 4,992,540 | 02/12/91 | Jamas <i>et al.</i> |
| | AA3 | 5,663,324 | 09/02/97 | Jamas <i>et al.</i> |
| | AB3 | 5,633,369 | 05/27/97 | Jamas <i>et al.</i> |
| <i>✓</i> | AC3 | 5,811,542 | 09/22/98 | Jamas <i>et al.</i> |
| | | | | |
| | | | | |
| | | | | |

| | |
|-----------------------|---------------------------|
| EXAMINER <i>cm</i> | DATE CONSIDERED 8-8-01 |
|-----------------------|---------------------------|

| | | | |
|--|---|--|-------|
| PTO-1449 RERODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 21, 2003 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 2732.1016-029 | APPLICATION NO. 101719432 Cont. App. of 09/841,179 | |
| | APPLICANT Spiros Jamas <i>et al.</i> | | |
| | FILING DATE | CONFIRMATION NO. | GROUP |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----|-----------------|-----------|-------------------|-----------------------|--|
| | | DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION YES NO | |
| <i>cm</i> | AL | 59210901 | 06-APR-95 | Japan (Abstract) | X | |
| | AM | 59045301 | 21-JUN-84 | Japan (Abstract) | X | |
| | AN | 56076401 | 11-SEP-81 | Japan (Abstract) | X | |
| | AO | 55071701 | 12-AUG-80 | Japan (Abstract) | X | |
| | AP | 20764118 | 02-DEC-81 | Great Britain | | |
| <i>cm</i> | AQ | 91/03495 | 21-MAR-91 | PCT International | | |
| | AL2 | WO 94/04163 | 03-MAR-94 | PCT International | | |
| <i>cm</i> | AM2 | WO 91/03248 | 31-MAR-91 | PCT International | | |
| <i>cm</i> | AN2 | 0463540 | 02-JAN-92 | EPO | | |
| <i>cm</i> | AO2 | 94/03498 | 17-FEB-94 | PCT International | | |
| <i>cm</i> | AP2 | 92/13896 | 20-AUG-92 | PCT International | | |
| <i>cm</i> | AQ2 | 94/03500 | 17-FEB-94 | PCT International | | |
| | AL3 | 0416343 | 13-MAR-91 | EPC | | |
| | AM3 | | | | | |
| | AN3 | | | | | |
| | AO3 | | | | | |
| | AP3 | | | | | |
| | AQ3 | | | | | |
| | AL4 | | | | | |
| | AM4 | | | | | |
| | AN4 | | | | | |
| | AO4 | | | | | |
| | AP4 | | | | | |
| | AQ4 | | | | | |
| | AL5 | | | | | |
| | AM5 | | | | | |

| | |
|-----------------------|---------------------------|
| EXAMINER <i>cm</i> | DATE CONSIDERED 4-3-05 |
|-----------------------|---------------------------|


| | | |
|---|--|--|
| PTO-1443 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 21, 2003 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 2732.1016-029 APPLICANT Spiros Jamas <i>et al.</i> FILING DATE | Sheet 3 of 6 APPLICATION NO. 10/719,432 Cont. App of 09/04/11, 179 CONFIRMATION NO. GROUP |
|---|--|--|

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|--|-----|--|
| cm | AR | Janusz, M.J., <i>et al.</i> , "Isolation of Soluble Yeast β -Glucans that Inhibit Human Monocyte Phagocytosis Mediated by β -Glucans Receptors," <i>J. Immunol.</i> , 137:3270-3276 (1986). |
| cm | AS | Manners, D.J., <i>et al.</i> , "The Structure of a β -(3)-D-Glucan from Yeast Cell Walls," <i>Biochem. J.</i> , 135:19-30 (1973). |
| cm | AT | Fleet, G.H., <i>et al.</i> , "Isolation and Composition of an Alkali-Soluble Glucan from the Cell Walls of <i>Saccharomyces cerevisiae</i> ," <i>J. Gen. Microbio.</i> , 94:180-192 (1976). |
| cm | AS | Miyazaki, T., <i>et al.</i> , "Structural Examination of Antitumour, Water-Soluble Glucans from <i>Grifora umbellata</i> by Use of Four Types of Glucanase," <i>Carbohydrate Research</i> , 65:235-243 (1978). |
| cm | AS | Reiskind, J.B. and Mullins, J.T., "Molecular Architecture of the Hyphal Wall of <i>Achlya ambisexualis</i> Raper. II. Ultrastructural Analyses and a Proposed Model," <i>Can. J. Microbiol.</i> , 27:1100-1105 (1981). |
| cm | AW | Latgé, J.P., <i>et al.</i> , "Composition Chimique et Ultrastructure des Parois des Hyphaux et des Azygospores de <i>Conidiobolus obscurus</i> ," <i>Can. J. Microbiol.</i> , 30:1507-1421 (1984). |
| | AS | Sherwood, E.R., <i>et al.</i> , "Soluble Glucan and Lymphokine-Activated Killer (LAK) Cells in the Therapy of Experimental Hepatic Metastases," <i>Chemical Abstracts</i> , 108:179752v (1988). |
| cm | AT | Hara, C., <i>et al.</i> , "A Branched (1-3)- β -D-Glucan from a Water Extract of <i>Dictyophora indusiata</i> FISCH," <i>Carb. Res.</i> , 145:237-246 (1986). |
| cm | AZ | Goldman, R., "Induction of a β -1,3-D-Glucan Receptor in P388D1 Cells Treated with Retinoic Acid of 1,25-dihydroxyvitamin D ₃ ," <i>Immunology</i> , 63:319-324 (1988). |
| cm | AR2 | Konopski, A., <i>et al.</i> , "Phagocytosis of β -1,3-D-Glucan-Derivatized Microbeads by Mouse Peritoneal Macrophages Involves Three Different Receptors," <i>Scand. J. Immunol.</i> , 33:297-306 (1991). |
| cm | AS2 | Williams, D.L., <i>et al.</i> , "Development of a Water-Soluble, Sulfated (1-3)- β -D-Glucan Biological Response Modifier Derived from <i>Saccharomyces cerevisiae</i> ," <i>Carbohydrate Research</i> , 235:247-257 (1992). |
| cm | AT2 | Williams, D.L., <i>et al.</i> , "A Sequential Multi-Assay Protocol for the Preclinical Assessment of Natural Product Complex Carbohydrate Immunomodulators," <i>Develop. Biol. Standard</i> , 77:129-136(1992). |

| | |
|--------------------|-------------------------------|
| EXAMINER cm | DATE CONSIDERED 4-3-05 |
|--------------------|-------------------------------|


| | | | | |
|--|---|------------------|---|--|
| PTO-1449 REDUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 21, 2003 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 2732.1016-029 | | APPLICATION NO. 10/719,432 Cont. App. 600/841,170 | |
| | APPLICANT Spiros Jamas <i>et al.</i> | | | |
| | FILING DATE | CONFIRMATION NO. | GROUP | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|--|-----|---|
| cm | AU2 | Williams, D.L., <i>et al.</i> , Development, Physiochemical Characterization and Preclinical Efficacy Evaluation of a Water Soluble Glucan Sulfate Derived from <i>Saccharomyces cerevisiae</i> , "Immunopharmacology, 22:139-156 (1991). |
| cm | AV2 | Bacon, J., <i>et al.</i> , "The Glucan Components of the Cell Wall of Baker's Yeast (<i>Saccharomyces cerevisiae</i>) Considered in Relation to its Ultrastructure," <i>Biochem. J.</i> , 114:557-567 (1969). |
| | AW2 | Vestnick Federalniho Uradu Pro Vynalezky, 10:111 (1989). |
| | AX2 | Vestnick Federalniho Uradu Pro Vynalezky, 11:122-123 (1989). |
| cm | AY2 | Onderdonk, A.B., <i>et al.</i> , "Anti-Infective Effect of Poly- β 1-6-Glucotrisyl- β 1-3-Glucopyranose Glucan <i>In Vivo</i> ," <i>Infect. Immun.</i> , 60:1642-1647 (1992). |
| cm | AZ2 | Abel, G. and Czop, J.K., "Activation of Human Monocyte GM-CSF and TNF- α Production by Particulate Yeast Glucan," International Congress for Infectious Diseases, Montreal Canada (Abstract) July 15-19, 1990. |
| cm | AR3 | Chihara, G., <i>et al.</i> , "Lentinan as a Host Defense Potentiator (HPD)," <i>Int. J. Immunotherapy</i> , 4:145-154 (1989). |
| cm | AS3 | Sherwood, E.R., <i>et al.</i> , "Enhancement of Interleukin-1 and Interleukin-2 Production by Soluble Glucan," <i>Int. J. Immunopharm.</i> , 9(3):261-267 (1987). |
| cm | AT3 | Williams, D.L., <i>et al.</i> , "Pre-clinical Safety Evaluation of Soluble Glucan," <i>Int. J. Immunopharm.</i> , 10(4):405-414 (1988). |
| cm | AU3 | Browder, W., <i>et al.</i> , "Beneficial Effect of Enhanced Macrophage Function in the Trauma Patient," <i>Ann. Surg.</i> , p. 605-613 (1990). |
| | AV3 | Jamas, <i>et al.</i>, "A Novel Class of Macrophage-Activating Immunomodulators," ACS Symposium Series, Polymeric Drugs and Delivery Systems, Chapter 5, pp. 44-51 (1991). |
| cm | AW3 | Shiota, M., <i>et al.</i> , "Comparison of β -Glucan Structures in a Cell Wall Mutant of <i>Saccharomyces cerevisiae</i> and the Wild Type," <i>J. Biochem.</i> , 98:1301-1307 (1985). |
| cm | AX3 | Jamas, <i>et al.</i> , "PGG-A Novel Class of Macrophage Activating Immunomodulators," International Congress for Infectious Diseases, Montreal, Canada (Abstract), July 15-19, 1990. |

| | |
|---|---------------------------|
| EXAMINER  | DATE CONSIDERED 4-3-05 |
|---|---------------------------|

| | | | | |
|---|---|------------------|--|--|
| PTO-1449 RETRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 21, 2003 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 2732.1016-029 | | APPLICATION NO. 10/719,432 Cont. App of 09/04/1,100 | |
| | APPLICANT Spiros Jamas <i>et al.</i> | | | |
| | FILING DATE | CONFIRMATION NO. | GROUP | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | |
|--|--|
| AY3 | Katzen, <i>et al.</i> , "PGG, a Glucose Polymer, Primes Interleukin-1 and Tumor Necrosis Factor Production," International Congress for Infectious Diseases, Montreal, Canada (Abstract), July 15-19, 1990. |
| AZ3 | Shah, <i>et al.</i> , "Influence of PGG on the Phagocytosis of <i>Staphylococcus aureus</i> or <i>Escherichia coli</i> ," International Congress for Infectious Diseases, Montreal, Canada (Abstract), July 15-19, 1990. |
| AX4 | Onderdonk, A.B., "Effect of a New Carbohydrate Polymer on Survival in a Mouse Model for Experimental <i>E. coli</i> Sepsis," International Congress for Infectious Diseases, Montreal, Canada (Abstract), July 15-19, 1990. |
| AS4 | Arbo, A. and Santos, J.L., "Effect of PGG on Neutrophil (PMN) Function in Experimental Malnutrition," International Congress for Infectious Diseases, Montreal, Canada (Abstract), July 15-19, 1990. |
| AX4 | Onderdonk, A.B., <i>et al.</i> , "Protective Effect of a New Carbohydrate Polymer in a Rat Model for Experimental Intraabdominal Sepsis," First International Congress on Biological Response Modifiers, Quebec, Canada, (Abstract), March, 1991. |
| AX4 | Lagrange, P.H. and Fourgeaud, M., "Enhanced Natural Resistance Against Severe Disseminated <i>Candida albicans</i> ," <i>Int'l J. Experimental Clin. Chemotherapy</i> , 40(1):48-55 (1991). |
| AV4 | Sakurai, <i>et al.</i> , "Intravenously Administered (1-3)- β -D-Glucan, SSG, Obtained from <i>Sclerotinia sclerotiorum</i> IFO9395 Augments Murine Peritoneal Macrophage Function <i>In Vivo</i> ," <i>Chem. Pharm. Bull.</i> , 40(8):2120-2124 (1992). |
| AW4 | Jamas, S., <i>et al.</i> , "PGG-A Novel Class of Macrophage Activating Immunomodulators," <i>Polymer Preprints</i> , 31:194-195 (1990). |
| AX4 | Sasaki, <i>et al.</i> , "Antitumor Activity of Degraded Products of Lentinan: Its Correlation with Molecular Weight," <i>Gann</i> , 67:191-195 (1976). |
| AY4 | Di Luzio, <i>et al.</i> , "Comparative Tumor-Inhibitory and Anti-Bacterial Activity of Soluble and Particulate Glucan," <i>Int. J. Cancer</i> , 24:773-779 (1979). |
| AZA | Burgaleta, C. and Golde, D.W., "Effect of Glucan of Granulopoiesis and Macrophage Genesis in Mice," <i>Cancer Research</i> , 37:1739-1742 (1977). |
| AR5 | Kenyon, A.J., "Delayed Wound Healing in Mice Associated with Viral Alteration of Macrophages," <i>Am. J. Vet. Res.</i> , 44(4):652-656 (1983). |

| | |
|---|---------------------------|
| EXAMINER  | DATE CONSIDERED 4-3-05 |
|---|---------------------------|

| | | | | |
|---|---|------------------|--|--|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 21, 2003 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 2732.1016-029 | | APPLICATION NO. 101779, 432 CONFIDENTIAL | |
| | APPLICANT Spiros Jamas <i>et al.</i> | | | |
| | FILING DATE | CONFIRMATION NO. | GROUP | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|--|-----|--|
| cm | AS5 | Babineau, T., <i>et al.</i> , "Randomized Phase I/II Trial of a Macrophage-Specific Immunomodulator PGG-Glucan (Betafectin™) in High Risk Surgery Patients," Clinical Congress of the American College of Surgeons, San Francisco, CA, October 11, 1993. |
| | AT5 | Babineau, T., <i>et al.</i> , "Randomized Multicenter Phase I/II Trial of a Macrophage-Specific Immunomodulator (PGG-Glucan) in High Risk Surgery Patients," Surgical Infection Society Meeting, April, 29, 1994. |
| cm | AUS | Adachi, Y., <i>et al.</i> , "Enhancement of Cytokine Production by Macrophages Stimulated with (1-3)-β-D-Glucan, Grifolan (GRN), Isolated from <i>Grifola frondosa</i> ," <i>Biol. Pharm. Bull.</i> , 17(12):1554-1560 (1994). |
| cm | AV5 | Babineau, T.J., <i>et al.</i> , "A Phase II Multicenter, Double-blind, Randomized, Placebo-Controlled Study of Three Dosages of an Immunomodulator (PGG-Glucan) in High Risk Surgical Patients", <i>Archives of Surgery</i> , 129:1204-1210 (1994). |
| cm | AW5 | Babineau, T.J., <i>et al.</i> , "Randomized Phase I/II Trial of a Macrophage-Specific Immunomodulator (PGG-Glucan) in High Risk Surgical Patients", <i>Annals of Surgery</i> , 220(5):601-609 (1994). |
| | AX5 | Norton, J.A., "Biological Therapy of Sepsis", <i>Annals of Surgery</i> , 220(5):599-600 (1994). |
| | AY5 | "Tumor Necrosis Factor: A Biological Enigma," <i>Science Impact</i> , pp. 5-6, June 1989. |
| | AZ5 | Dinarello, C.A. and Neta, R., "An Overview on Interleukin-1 as a Therapeutic Agent", <i>Biotherapy</i> , 1:245-254 (1989). |
| | AR6 | Van der Meer, J.W.M., <i>et al.</i> , "Concentrations of Immunoreactive Human Tumor Necrosis-Factor Alpha Produced by Human Mononuclear Cells In Vitro," <i>Journal of Leukocyte Biology</i> , 43:216-223 (1988). |
| | AS6 | Dinarello, C.A., "Interleukin-1," <i>Reviews of Infectious Diseases</i> , 6(1):51-95 (1984). |
| | AT6 | Duvic, M., <i>et al.</i> , "Glucan-Induced Keratoderma in Acquired Immunodeficiency Syndrome," <i>Arch Dermatol.</i> , 123:751-756 |
| | AU6 | Adachi, Y., <i>et al.</i> , "Macrophage Activation in Vitro by Chemically Cross-Linked (1-3)-β-D-Glucans," <i>Chem. Pharm. Bull.</i> , 38(4):988-992 (1990). |
| | AV6 | Sietsma, J.H. and Wessels, J.G.H., "Solubility of (1-3)-β-D-Glucan in Fungal Walls: Importance of Presumed Linkage between Glucan and Chitin", <i>J. Gen. Microbiology</i> , 125:209-212 (1981). |

| | |
|---|---------------------------|
| EXAMINER  | DATE CONSIDERED 4-3-05 |
|---|---------------------------|